Evaluation of the Analgesic Efficacy of Lu AG06474 in Healthy Adult Subjects with Induced Pain

The primary objective of this clinical trial is to evaluate the **pain**-relieving properties of Lu AG06474 in healthy adult participants. Understanding the efficacy of Lu AG06474 in alleviating pain is clinically relevant as it may contribute to the development of new therapeutic options for pain management. The study focuses on assessing the potential of this investigational product to provide relief from pain, which is a significant concern in clinical practice due to its impact on quality of life and overall health outcomes.

The clinical trial involves participants experiencing **pain**. The study population includes both male and female subjects, with an age range category code of 3, which typically corresponds to adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the **pain**-relieving properties of Lu AG06474 in healthy adult participants. This study is a Phase 3 trial, which is a critical stage in the clinical research process, aimed at confirming the efficacy and monitoring the side effects of the investigational product. The trial follows a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is October 6, 2023, with the trial expected to conclude by April 28, 2024, marking the overall trial duration.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. This initial visit is crucial for determining eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to either the treatment group receiving Lu AG06474 or a control group. Throughout the trial, participants will attend scheduled follow-up visits to monitor their response to the treatment and assess any adverse effects. These visits are essential for collecting data on the primary and secondary endpoints of the study.

The end-of-study visit will occur at the conclusion of the trial period, where final assessments will be conducted to evaluate the overall outcomes of the treatment. The expected length of participant involvement is approximately six months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on October 6, 2023, with an estimated end date of April 28, 2024. The efficacy of the investigational treatment will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The use of validated scales, laboratory tests, or patient-reported outcomes may be involved in the assessment process, although specific tools or instruments are not mentioned. The trial's objective is to provide robust data on the treatment's efficacy, contributing to the understanding of its potential benefits in the targeted medical condition.